About AN2 Therapeutics, Inc.
https://www.an2therapeutics.comAN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
CEO
Eric E. Easom
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
ALMITAS CAPITAL LLC
Shares:1.43M
Value:$1.87M
VANGUARD GROUP INC
Shares:1.08M
Value:$1.41M
PFIZER INC
Shares:715.29K
Value:$937.04K
Summary
Showing Top 3 of 39
About AN2 Therapeutics, Inc.
https://www.an2therapeutics.comAN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $10.04M ▲ | $-9.35M ▼ | 0% | $-0.31 ▼ | $-9.35M ▼ |
| Q2-2025 | $0 | $7.22M ▼ | $-6.46M ▲ | 0% | $-0.21 ▲ | $-7.22M ▲ |
| Q1-2025 | $0 | $11.54M ▲ | $-10.65M ▼ | 0% | $-0.35 ▼ | $-11.54M ▼ |
| Q4-2024 | $0 | $8.6M ▼ | $-7.52M ▲ | 0% | $-0.25 ▲ | $0 ▲ |
| Q3-2024 | $0 | $14.01M | $-12.75M | 0% | $-0.43 | $-11.77M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $61.92M ▼ | $67.23M ▼ | $6.86M ▼ | $60.38M ▼ |
| Q2-2025 | $62.92M ▼ | $75.83M ▼ | $6.98M ▼ | $68.84M ▼ |
| Q1-2025 | $67.06M ▼ | $81.34M ▼ | $8.01M ▼ | $73.33M ▼ |
| Q4-2024 | $83.62M ▼ | $92.09M ▼ | $10.24M ▲ | $81.85M ▼ |
| Q3-2024 | $93.43M | $97.69M | $10.02M | $87.67M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-9.35M ▼ | $-6.38M ▲ | $6.11M ▲ | $48K ▲ | $-217K ▲ | $-6.38M ▲ |
| Q2-2025 | $-6.46M ▲ | $-7.6M ▲ | $5.83M ▼ | $0 ▼ | $-1.76M ▼ | $-7.6M ▲ |
| Q1-2025 | $-10.65M ▼ | $-10.62M ▼ | $9.19M ▲ | $65K ▲ | $-1.37M ▲ | $-10.62M ▼ |
| Q4-2024 | $-7.52M ▲ | $-5.27M ▲ | $-6.88M ▼ | $0 ▼ | $-12.15M ▼ | $-5.27M ▲ |
| Q3-2024 | $-12.75M | $-12.01M | $18.72M | $23K | $6.74M | $-12.01M |
CEO
Eric E. Easom
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
ALMITAS CAPITAL LLC
Shares:1.43M
Value:$1.87M
VANGUARD GROUP INC
Shares:1.08M
Value:$1.41M
PFIZER INC
Shares:715.29K
Value:$937.04K
Summary
Showing Top 3 of 39